At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 76 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)
In Brief
A Phase 3 clinical trial evaluating liraglutide and placebo for Type 2 Diabetes. Completed, enrolled 76 participants across 6 sites.
Detailed Summary
Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesSpain
CollaboratorsDynamic Solutions, Novo Nordisk A/S
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedSep 5, 2016
Enrollment StartOct 4, 2016
Primary CompletionNov 18, 2019
Study CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.8 years ago
Interventions
liraglutidedrug
7-week subcutaneous liraglutide once daily
placebodrug
7-week subcutaneous placebo once daily